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Background: Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell
carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to
determine if sorafenib target expression is predictive of sorafenib sensitivity.
Methods: We used an automated, quantitative immunofluorescence-based method to determine expression levels
of sorafenib targets VEGF, VEGF-R1, VEGF-R2, VEGF-R3, c-RAF, B-RAF, c-Kit, and PDGFR-β in a cohort of 96 patients
treated with sorafenib. To measure vasculature in the tumor samples, we measured microvessel area (MVA) by
CD-34 staining.
Results: Of the markers studied, only high MVA was predictive of response (p = 0.005). High MVA was associated
with smaller primary tumors (p = 0.005). None of the biomarkers studied was predictive of overall or progression-
free survival. Using the Bonferroni adjustment correcting for 9 variables with an alpha of 0.05, MVA remained
significantly associated with sorafenib response.
Conclusions: Our results suggest that high MVA in tumor specimens might be associated with a greater likelihood
of response to therapy. Further studies are needed to confirm these results in additional patients and in patients
receiving other VEGF-R2 inhibitors, as MVA might be useful to improve patient selection for VEGF-R2 inhibitors.
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Despite emergence of new drugs for patients with unre-
sectable or metastatic RCC (mRCC), most therapies are
not curative. Response rates are 15-44%, and the five-year
survival for mRCC is only 10% [1]. Immunotherapy once
represented the standard treatment; responses to interferon-
alpha are approximately 12% and typically not durable,
whereas response rates to high-dose interleukin-2 are
approximately 14%, and often durable [2,3]. Although
newer therapies such as Nivolumab are promising,
there remains great need for additional therapies, along
with predictive biomarkers to improve the therapeutic
window [4].
Mutations or silencing of the von Hippel-Lindau tumor-
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stated.most prevalent mRCC sub-type [5]. VHL silencing leads
to dysregulated hypoxia-induced factors and activation of
downstream pathways important for tumor progression
[6]. The upregulation of vascular endothelial growth factor
(VEGF), platelet derived growth factor (PDGF), and other
pro-angiogenic proteins have led to development of ther-
apies targeting angiogenesis and VEGF pathway members
in RCC [7].
There is a variety of Food and Drug Administration
(FDA) approved targeted therapies for mRCC. These in-
clude tyrosine kinase inhibitors (TKIs), sunitinib, sorafe-
nib, pazopanib, and axitinib, which primarily target VEGF
receptors. Other drugs include the anti-VEGF antibody
bevacizumab given with interferon and mTOR inhibitors,
temsirolimus and everolimus [8].
Sorafenib, initially identified as a Raf kinase inhibitor,
was the first FDA-approved anti-angiogenic multikinase
inhibitor for mRCC. Sorafenib inhibits C-RAF, B-RAF,
VEGFR-2, VEGF-R3, PDGFR-β, c-KIT and FLT-3 [9].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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R2. A randomized discontinuation placebo-controlled phase
II trial demonstrated prolonged progression-free-survival
(PFS) in patients receiving sorafenib [10]. In a random-
ized phase III trial, the Treatment Approaches in Renal
Cancer Global Evaluation Trial (TARGET), sorafenib
prolonged median PFS from 2.8 to 5.5 months. Although
the initial intent-to-treat analysis did not show a signifi-
cant overall survival (OS) benefit, a secondary analysis,
censoring placebo-treated patients who crossed over to
sorafenib, demonstrated a survival advantage for those re-
ceiving sorafenib [11,12]. Several biomarkers have been
studied as potential predictors of sorafenib response, to
improve patient selection. Kusuda et al. assessed the asso-
ciation between expression of 19 molecular markers by
immunohistochemistry and response to sorafenib in 45
mRCC patients. Bcl-xL, PDGFR-α, bone metastasis, and
c-reactive protein levels were associated with PFS by
univariate analysis. On multivariable analysis, PDGFR-α
maintained significance [13]. Jonasch et al. evaluated ex-
pression and activation of phosphoinositide-3-kinase path-
way members in tumors of 22 sorafenib-treated patients
and 18 treated with sorafenib/interferon. High pAKT was
associated with worse PFS [14]. Using tumor and plasma
samples of patients enrolled on the TARGET trial, Peña
et al. showed that soluble plasma VEGFR-2 and CAIX,
TIMP-1, Ras p21, and VHL mutations in tumors were not
predictive of sorafenib response [15]. In 83 mRCC patients
treated with sorafenib, a low erythrocyte sedimentation
rate was predictive of improved PFS [16]. Zurita et al.
demonstrated that low IL-2, IL-5, and monocyte chemo-
tactic protein 1, and high EGF, IL-12 p40, and M-CSF
were correlated with shorter PFS [17].
The association between tumor vascularity and re-
sponse to VEGF and VEGF-receptor targeting drugs has
been studied in small series. In pilot studies, vascular
permeability decreased after sorafenib treatment, cor-
relating with time to progression (P = 0.01). Elevated
baseline tumor vascular permeability, defined by Dy-
namic Contrasted-Enhanced-Magnetic Resonance Im-
aging (DCE-MRI), correlated well with improved PFS
(P = 0.003), but not with radiographic decrease in tumor
size [18].
Pretreatment prognostic clinical variables which form
the MSKCC score have been well established in mRCC.
Poor Karnofsky performance status, high serum lactate
dehydrogenase (LDH), low hemoglobin, and high serum
calcium are associated with poor OS [19]. In the TAR-
GET trial, MSKCC score was an independent predictor
of OS in both placebo and sorafenib-treated patients
[12]. We studied associations between pre-treatment
tissue levels of sorafenib targets and microvessel area
(MVA) and sorafenib activity in sorafenib-treated pa-
tients. Traditional immunohistochemical analyses arelimited by subjectivity and qualitative assessment. We
employed a method of automated, quantitative analysis
(AQUA) to determine levels of sorafenib targets (B-Raf,
C-RAF, cKIT, PDGF-Rβ, VEGF-R1, VEGF-R2, VEGF-
R3, VEGF) and MVA [20-22]. We found no correlation
between expression of these markers, PFS and OS, al-
though high MVA was associated with a greater likeli-
hood of response.
Patients and methods
Tissue microarray (TMA) construction
With approval of institutional review boards at Institut
Gustave Roussy and Yale University, we identified 116
sorafenib-treated mRCC patients, of which 96 had
ample viable tissue. The majority was enrolled in the
TARGET study by the Institut Gustave Roussy, while
others were enrolled in the randomized phase 2 front
line study, or in the expanded access program, and 7
were treated at Yale after approval of sorafenib [23,24].
Previous treatments included high-dose IL-2, inter-
feron, IL-2 and interferon, interferon and bevacizumab,
provera, interferon and velban, cisplatin and gemcita-
bine, and sunitinib. Nine patients received prior VEGF/
VEGFR targeting drugs. Four received sunitinib, three
received prior bevacizumab and two received both.
TMAs were constructed using 0.6 mm cores spaced
0.8 mm apart. Nephrectomy specimens were used for
these analyses, based on tissue availability. In previous
studies we showed that MVA and expression patterns
of sorafenib targets were not different in metastatic and
matched primary tumors [25,26]. Tumors from each
patient were represented by three cores from different
areas, avoiding areas of necrosis. Demographics, clinical
characteristics, MSKCC risk factors and response to so-
rafenib are summarized in Table 1. Follow up time
ranged from two to 87 months, median 14.5 months.
Immunofluorescence
Slides were stained individually for target markers; B-
RAF, C-RAF, cKIT, PDGF-Rβ, VEGF-R1, VEGF-R2,
VEGF-R3, VEGF. Immunofluorescent staining was per-
formed as described [20,27]. CD-34 staining was used to
determine MVA, as described [21,22]. MVA was deter-
mined by percent area of CD-34 staining within the
tumor mask area. Details of antibodies and dilutions are
provided in Additional file 1: Table S1 [25,26].
To determine specificity of each antibody lot, we per-
formed immunoblotting to verify binding to a single band
at the expected molecular weight (not shown). A number
of commercially available VEGF-R2 antibodies were
tested. As previously described, the A-3 antibody (Santa
Cruz Biotechnologies, Inc, Santa Cruz, CA) was superior
in our hands to the 5B11 (Cell Signaling Technologies,
Danvers, MA) [26].
Table 1 Patient characteristics







Fuhrman Grade 0.074 0.7862
1-2 4 13
3-4 10 39
Tumor Size 1.311 0.2522
<=75 mm 9 23
>75 mm 5 26
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Image analysis algorithms have been previously de-
scribed and adapted for RCC tissues [20,22]. The per-
centage of CD-34 area within the tumor area was used
to determine MVA [25].
Statistical analysis
We used JMP 5.0 software for data analysis (SAS Insti-
tute, Cary, NC). Scores for replicate tumor cores were
averaged. Associations between biomarkers and binar-
ized clinical parameters were performed by ANOVA.
Survival analyses were done using the Cox proportional
hazards method, and survival curves generated using the
Kaplan Meier method.
Results
We first explored associations between known clinical
prognostic parameters and outcome in these sorafenib-
treated patients. Patients were assigned to two groups
using RECIST 1.0 (response evaluation criteria in solid
tumors) to determine the best response: partial and
complete response (PR, CR) or stable and progressivedisease (SD, PD). Scans were assessed by the institutional
radiologist and the treating oncologist. The percentage
of patients with PR and CR was higher than typically
seen in sorafenib-treated patients [11]. We also studied
the association between established prognostic markers
and PFS and OS. Lung metastases were associated with
a greater likelihood of response to sorafenib (χ2 = 3.953,
p = 0.0468) and prolonged PFS (p = 0.0317), while me-
tastases in other locations were not associated with re-
sponse or survival. Patients with low hemoglobin had
shorter PFS, as did patients with poor performance sta-
tus (log rank p < 0.0001 for both). High LDH, advanced
age, and male gender were associated with shorter PFS,
but this was not statistically significant. Clinical vari-
ables associated with worse OS included bone metasta-
ses (p = 0.0051), low hemoglobin (p = 0.0024) and poor
performance status (p < 0.0001).
We next determined the association between biomarker
expression and response to sorafenib. Additional file 1:
Table S2 contains AQUA score distributions. Figure 1A
shows an example of a highly vascular tumor, stained with
anti-CD-34, Figure 1B a less vascular tumor.
Figure 1 High (panel A) and low (panel B) microvessel area
(MVA) by AQUA. We used a cocktail of anti-cytokeratin and anti-
carbonic anhydrase-9 conjugated to Cy2 to create a tumor mask
(green), and anti-CD-34 conjugated to Cy5 (red) to identify microvessels.
An example of a patient with high MVA is shown in panel A, and an
example of low MVA in panel B. The corresponding MVA scores were
28.37% and 3.31%.
Figure 2 Means plot analysis depicting differences in MVA
between sorafenib non-responders (progressive disease and
stable disease) and responders (partial and complete responders).
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AQUA scores for each marker and sorafenib response
using a two-sample t-test. High MVA was associated with
a greater likelihood of response (p = 0.005) (Figure 2).
This association was independent of other known pre-
dictive markers (performance status, LDH, calcium and
hemoglobin). Expression of sorafenib targets in tumor
cells was not correlated with response (Table 2). We di-
chotomized continuous AQUA scores into high and low
expressers by the median for each marker. High C-Raf
was associated with improved OS but not PFS (data not
shown). No other markers were significantly associated
with either PFS or OS. Using the Bonferroni adjustment
correcting for 9 variables with an average inter-variable
correlation of 0.4, an alpha of 0.05 is reduced to 0.013.Consequently MVA remained significantly associated with
sorafenib response.
We then determined whether marker expression or
vascularity was associated with other clinical/patho-
logical characteristics by ANOVA, including age at diag-
nosis (binarized at 50 years), gender, primary tumor size
(dichotomized by median size, 75 mm), and Fuhrman
Grade (I/II versus III/IV). High MVA was associated
with small primary tumors (p = 0.0273). Associations
between marker expression and prognostic variables
are shown in Additional file 1: Table S3. High tumor
VEGF-R2 and PDGF-Rβ were associated with poor per-
formance status (p = 0.043 and p = 0.023). High VEGF
was associated with high LDH (p = 0.032). High tumor
VEGF-R2, high VEGF-R3 and high PDGF-Rβ were
associated with low hemoglobin (p = 0.006, p = 0.036,
p = 0.044, respectively). The number of patients with el-
evated LDH and calcium was small. For all other
markers, there was no significant association between
expression and clinical variables.
Discussion
Here we quantified intensity of sorafenib target expres-
sion and determined vessel area in nephrectomy speci-
mens of mRCC patients treated with sorafenib. MVA in
nephrectomy was predictive of sorafenib response. Ex-
pression levels of direct sorafenib targets were not asso-
ciated with response or PFS. MVA was also associated
with small primary tumors. The cohort of specimens
available to us was enriched for patients who achieved
a response; 19% had either a partial or complete re-
sponse, whereas of the 451 sorafenib-treated patients in
the TARGET trial, 44 (10%) responded [11]. This re-
sponse rate is similar to that recently reported in an-
other study [28].
Table 2 Associations between markers and response to sorafenib
Mean +/- STD
Marker Responders Non-responders Delta t-statistic p-value
MVA 10.3 +/- 9.7 5.6 +/- 4.2 4.7 2.847 0.0055
VEGF 33.4 +/- 11.2 38 +/- 10.9 -4.6 -1.548 0.125
VEGF-R1 32.4 +/- 7.6 33 +/- 8.2 -0.6 -0.288 0.7739
VEGF-R2 31.4 +/- 8.3 33.4 +/- 8.0 -2 -0.929 0.3554
VEGF-R3 48.3 +/- 13.3 50.9 +/- 10.2 -2.6 -0.879 0.3817
c-RAF 35.1 +/- 14.9 34.4 +/- 13.5 0.7 -0.177 0.8601
B-RAF 39.5 +/- 12.8 42 +/- 14.1 -2.5 -0.707 0.4813
c-Kit 44.0 +/- 12.8 43.8 +/- 12.4 0.2 -0.047 0.9629
PDGFR-β 37.5 +/- 14.9 33.6 +/- 9.5 3.9 -1.321 0.1897
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compared to placebo when censored at cross-over, and
longer PFS when compared to placebo [12]. Sorafenib
has since become the standard arm to which newer ther-
apies are being compared [28]. The low response rate to
sorafenib, however, provides the rationale for predictive
biomarker studies to improve the therapeutic ratio.
Renal cell carcinomas are highly vascular. Tumor
MVA is the most commonly used measure of angiogen-
esis, and in previous studies we showed that MVA in
primary tumors is associated with decreased OS [22].
Others have confirmed this finding [29]. In a more recent
publication, we found no major differences in MVA of
nephrectomy specimens and matched metastatic tumors
[25]. This suggests that for predictive biomarker marker
studies, such as the one undertaken here, the primary
tumor can be used as a surrogate for measuring vascular-
ity in metastatic deposits. This provides a practical means
to determine tumor vascularity when treating metastatic
disease, as needle biopsies from metastatic sites might not
yield sufficient tumor. However, seeing that sorafenib is
currently used primarily in the second line setting, base-
line MVA at the time of initial diagnosis might be altered.
MVA might need to be reassessed at the time of initiation
of a new VEGF/VEGFR inhibitor.
In our previous studies we found that MVA does not
correlate well with expression levels of VEGF and its re-
ceptors. These studies were done in a large tumor co-
hort of over 300 cases [22]. This is likely due to the fact
that additional growth factors determine vessel density,
and these are likely not affected by sorafenib.
It is unclear whether sorafenib inhibits tumor growth
by inhibiting angiogenesis or by direct inhibition of drug
targets in tumor cells. Our results suggest that the
former might be the more important mechanism of
action of the drug, supported by other small studies
using DCE-MRI, showing an association between base-
line tumor vascularity and greater benefit from sorafenib[18]. Patients with mRCC and prior nephrectomy with
available tissue can thus be assessed for likelihood of so-
rafenib response by a simple tissue based assay, such as
the one used here, rather than by more expensive imaging
modalities. We hypothesize that the inhibitory effect of
sorafenib on angiogenic factors and their receptors effec-
tively lowers MVA, resulting in decreased tumor viability,
a hypothesis that is supported by Flaherty et al. who found
a decrease in tumor vascularity from baseline in sorafenib-
treated patients responding to therapy [18]. Highly vascu-
lar tumors might be more susceptible to sorafenib, as these
tumors may be more dependent on the vasculature to
proliferate.
Although it has been over nine years since sorafenib has
been approved by the Food and Drug Administration, no
predictive assays have been validated for this drug (or any
of the other approved VEGF or VEGFR inhibitors). A clin-
ical trial has been completed assessing the association be-
tween response to sorafenib and bevacizumab and a
variety of tissue based biomarkers including MVA, as well
as imaging based predictors (NCT00126503). The results
have not been published. Recent studies by Zhao et al.
suggests that high MVA predicts better response to beva-
cizumab in non small cell lung cancer [30]. VHL muta-
tions might be associated with benefit from VEGF/VEGFR
targeting drugs, and we are currently assessing the associ-
ation between VHL mutations and clinical benefit from
sorafenib and other drugs in RCC tumors.
In our cohort, high MVA in nephrectomy samples was
associated with smaller primary tumors. A large recent
study showed a distinct subpopulation of RCC patients
with smaller primary tumors who developed distant me-
tastasis [31]. This subpopulation might be the patients
more likely to respond to anti-angiogenic therapy. Ex-
pression of some of the angiogenic factors studied here
was associated with worse clinical features, such as poor
performance status and low hemoglobin, but not with
response to therapy.
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sorafenib in combinatorial studies, but a superior com-
bination has not been identified [28]. Alternative VEGF-
receptor inhibitors are available for clinical use, many
with superior response rates to sorafenib. However, all
are associated with toxicities, and due to the relatively
favorable toxicity profile of sorafenib, the drug is still
used, either in the second line setting, or for patients
who do not tolerate other drugs in this class [32].
In summary, in our study we found an association be-
tween microvessel area in nephrectomy specimens and re-
sponse to sorafenib. Use of MVA as a predictor of
response should be validated and confirmed in additional
RCC cohorts. Furthermore, our results suggest that MVA
should be studied as a potential predictor of response to
other anti-angiogenic therapies as well.
Additional file
Additional file 1: Table S1. Antibody source and dilution information.
Table S2. AQUA score distributions for markers analyzed. Table S3.
Correlations between AQUA scores and clinical variables.
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